Senzime is a Swedish medical technology company specializing in real-time patient monitoring solutions for neuromuscular and respiratory functions. The company aims to eliminate anesthesia and respiratory-related complications, thereby reducing healthcare costs associated with surgical and high-acuity procedures. Senzime's flagship product, ExSpiron 2Xi, offers non-invasive Respiratory Volume Monitoring (RVM), providing accurate, real-time measurements of respiratory status. This technology serves as an early indicator of changes in a patient's respiratory condition, which can be critical in preventing complications.

Senzime operates in the global healthcare market, with its headquarters and production facilities located in Uppsala, Sweden, and subsidiaries in the United States and Germany. The company serves a diverse range of clients, including hospitals, surgical centers, and healthcare providers who require advanced patient monitoring systems to improve patient outcomes and operational efficiency.

The business model of Senzime revolves around the development, production, and sale of its proprietary medical devices. The company generates revenue through direct sales, licensing agreements, and strategic acquisitions. For instance, Senzime has a licensing agreement with Fukuda Denshi in Japan and has acquired companies like Acacia Designs B.V. and MD Biomedical AB to broaden its product range and capabilities.

Senzime's mission is to create long-term value for customers, shareholders, and society by providing state-of-the-art, algorithm-powered patient monitoring solutions. The company is listed on the Nasdaq Stockholm main market, which underscores its commitment to growth and innovation in the medical technology sector.

Keywords: patient monitoring, respiratory functions, neuromuscular, anesthesia, healthcare, non-invasive, real-time, medical technology, Nasdaq Stockholm, global market.